Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy
Abstract Background and Aims Pediatric‐type low‐grade gliomas (pLGGs) are the most common solid tumors in children, with v‐raf murine sarcoma viral oncogene homolog B (BRAF) mutations playing a significant role in their development. Dabrafenib and trametinib are targeted therapies that are recently...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.1841 |
| _version_ | 1827362994692030464 |
|---|---|
| author | Marrium Sultan Dar Nayab Shahid Arisha Waqas Yumna Arif Baig Aimen Waqar Khan |
| author_facet | Marrium Sultan Dar Nayab Shahid Arisha Waqas Yumna Arif Baig Aimen Waqar Khan |
| author_sort | Marrium Sultan Dar |
| collection | DOAJ |
| description | Abstract Background and Aims Pediatric‐type low‐grade gliomas (pLGGs) are the most common solid tumors in children, with v‐raf murine sarcoma viral oncogene homolog B (BRAF) mutations playing a significant role in their development. Dabrafenib and trametinib are targeted therapies that are recently approved by Food and Drug Administration for pediatric patients with pLGG harboring a BRAF V600E mutation. Body This study emphasizes the role of Dabrafenib and Trametinib in pLGG. A multicenter Phase I/II trial demonstrated the superior efficacy of dabrafenib plus trametinib (D+T) compared to carboplatin plus vincristine (C+T), with higher overall response rates, clinical benefit rates, and longer progression‐free survival. The safety profile of dabrafenib plus trametinib (D+T) was favorable, with fewer discontinuations and adverse events compared to the control group. Conclusion The introduction of D+T as a targeted therapy represents a significant advancement in the management of pLGG, necessitating further investigations to understand its long‐term consequences and optimize patient care. |
| first_indexed | 2024-03-08T07:38:34Z |
| format | Article |
| id | doaj.art-e6f1f96bf5484a26941693b1058f8737 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-03-08T07:38:34Z |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-e6f1f96bf5484a26941693b1058f87372024-02-02T18:04:59ZengWileyHealth Science Reports2398-88352024-01-0171n/an/a10.1002/hsr2.1841Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapyMarrium Sultan Dar0Nayab Shahid1Arisha Waqas2Yumna Arif Baig3Aimen Waqar Khan4Department of Medicine Jinnah Sindh Medical University Karachi PakistanDepartment of Medicine Jinnah Sindh Medical University Karachi PakistanDepartment of Medicine Jinnah Sindh Medical University Karachi PakistanDepartment of Medicine Jinnah Sindh Medical University Karachi PakistanDepartment of Medicine Jinnah Sindh Medical University Karachi PakistanAbstract Background and Aims Pediatric‐type low‐grade gliomas (pLGGs) are the most common solid tumors in children, with v‐raf murine sarcoma viral oncogene homolog B (BRAF) mutations playing a significant role in their development. Dabrafenib and trametinib are targeted therapies that are recently approved by Food and Drug Administration for pediatric patients with pLGG harboring a BRAF V600E mutation. Body This study emphasizes the role of Dabrafenib and Trametinib in pLGG. A multicenter Phase I/II trial demonstrated the superior efficacy of dabrafenib plus trametinib (D+T) compared to carboplatin plus vincristine (C+T), with higher overall response rates, clinical benefit rates, and longer progression‐free survival. The safety profile of dabrafenib plus trametinib (D+T) was favorable, with fewer discontinuations and adverse events compared to the control group. Conclusion The introduction of D+T as a targeted therapy represents a significant advancement in the management of pLGG, necessitating further investigations to understand its long‐term consequences and optimize patient care.https://doi.org/10.1002/hsr2.1841dabrafenibpediatric low‐grade gliomapLGGtrametinib |
| spellingShingle | Marrium Sultan Dar Nayab Shahid Arisha Waqas Yumna Arif Baig Aimen Waqar Khan Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy Health Science Reports dabrafenib pediatric low‐grade glioma pLGG trametinib |
| title | Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy |
| title_full | Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy |
| title_fullStr | Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy |
| title_full_unstemmed | Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy |
| title_short | Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy |
| title_sort | dabrafenib plus trametinib a breakthrough in pediatric low grade glioma therapy |
| topic | dabrafenib pediatric low‐grade glioma pLGG trametinib |
| url | https://doi.org/10.1002/hsr2.1841 |
| work_keys_str_mv | AT marriumsultandar dabrafenibplustrametinibabreakthroughinpediatriclowgradegliomatherapy AT nayabshahid dabrafenibplustrametinibabreakthroughinpediatriclowgradegliomatherapy AT arishawaqas dabrafenibplustrametinibabreakthroughinpediatriclowgradegliomatherapy AT yumnaarifbaig dabrafenibplustrametinibabreakthroughinpediatriclowgradegliomatherapy AT aimenwaqarkhan dabrafenibplustrametinibabreakthroughinpediatriclowgradegliomatherapy |